EUVIMEDEUVIMED entdecken
Crossref

Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases

Daniel Ward, Nynne Nyboe Andersen, Sanne Gørtz, Aske Thorn Iversen, Kristine Højgaard Allin, Laurent Beaugerie, Julien Kirchgesner, Tine Jess

Clinical Gastroenterology and Hepatology · 2024-01 · 22 (1) · 135-143.e8

DOI: 10.1016/j.cgh.2023.06.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-01. Verfasst von Daniel Ward und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark. El…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Inflammatory Bowel Diseases, Arthritis, Rheumatoid, Psoriasis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Danmarks Grundforskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Tumor necrosis factor inhibitors (anti-TNF) are effective therapies for several immune-mediated inflammatory diseases (IMIDs). However, case reports have identified the paradoxical occurrence of IMIDs in patients treated with anti-TNF. We studied the risk of rheumatoid arthritis, psoriasis, and hidradenitis suppurativa after the initiation of anti-TNF therapy for inflammatory bowel disease (IBD). METHODS: We conducted 2 nationwide cohort studies comprising all patients with IBD in Denmark (2005-2018) and France (2008-2018). We obtained individual-level information on exposure to anti-TNF, diagnoses of IMIDs including rheumatoid arthritis, psoriasis, and hidradenitis suppurativa, and potential confounders from healthcare registers in the respective countries. We used Cox models to estimate hazard ratios (HRs) for the association between anti-TNF exposure and IMIDs and then pooled the estimates from the 2 cohorts. To test the robustness of our results, we performed an active comparator analysis of anti-TNF monotherapy vs azathioprine monotherapy. RESULTS: The Danish and French cohorts comprised 18,258 and 88,786 subjects with IBD, respectively, contributing a total of 516,055 person-years of follow-up. Anti-TNF was associated with an increased risk of rheumatoid arthritis, psoriasis, and hidradenitis suppurativa in both the Danish (HR, 1.66; 95% confidence interval [CI], 1.34-2.07) and the French cohort (HR, 1.78; 95% CI, 1.63-1.94), with a pooled HR of 1.76 (95% CI, 1.63-1.91). Anti-TNF was also associated with an increased risk of the outcomes when compared with azathioprine (pooled HR, 2.94; 95% CI, 2.33-3.70). CONCLUSIONS: In 2 nationwide cohorts of IBD patients, anti-TNF therapy was associated with an increased risk of rheumatoid arthritis, psoriasis, and hidradenitis suppurativa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaInflammatory Bowel DiseasesArthritis, RheumatoidPsoriasisHumansTumor Necrosis Factor InhibitorsAzathioprineTumor Necrosis Factor-alphaImmunomodulating Agents

Stichwörter der Autor:innen

Inflammatory Bowel DiseaseTumor Necrosis Factor Inhibitors

Substanzen

Tumor Necrosis Factor InhibitorsAzathioprineTumor Necrosis Factor-alphaImmunomodulating Agents

Autor:innen und Institutionen

  • Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark. Electronic address: djwa@dcm.aau.dk.
  • Section of Gastroenterology, Medical Department, Zealand University Hospital, Køge, Denmark.
  • Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
  • Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology & Hepatology, Aalborg University Hospital…
  • INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France.

Förderung

  • Danmarks Grundforskningsfond

Zitieren

APA

Ward, D., Nyboe Andersen, N., Gørtz, S., Thorn Iversen, A., Højgaard Allin, K., Beaugerie, L., Kirchgesner, J., & Jess, T. (2024). Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases. Clinical Gastroenterology and Hepatology, 22(1), 135-143.e8. https://doi.org/10.1016/j.cgh.2023.06.025

Vancouver

Ward D, Nyboe Andersen N, Gørtz S, Thorn Iversen A, Højgaard Allin K, Beaugerie L, et al. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases. Clinical Gastroenterology and Hepatology. 2024;22(1):135-143.e8. doi:10.1016/j.cgh.2023.06.025

BibTeX
@article{Ward2024,
  author = {Ward, Daniel and Nyboe Andersen, Nynne and Gørtz, Sanne and Thorn Iversen, Aske and Højgaard Allin, Kristine and Beaugerie, Laurent and Kirchgesner, Julien and Jess, Tine},
  title = {Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {1},
  pages = {135--143.e8},
  doi = {10.1016/j.cgh.2023.06.025}
}
Kostenlos starten →